GuruFocus.com
Stora Enso Oyj (SEOAY) Full Year 2025 Earnings Call Highlights: Strategic Milestones and Market ...
📊
AI Sentiment
Positive
6/10
- Home
- IMVT
IMVT
Immunovant Inc.
as of 02-05-2026 3:37pm EST
$24.22
$0.93
-3.70%
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.3B | IPO Year: | N/A |
| Target Price: | $29.13 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.72 - $27.80 | Next Earning Date: | 02-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -431335000.0 | FCF Growth: | N/A |
AI-Powered IMVT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.79%
71.79%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
Stout Jay S
Sell
Chief Technology Officer
IMVT Jan 21, 2026
Avg Cost/Share
$26.03
Shares
1,977
Total Value
$51,461.31
Owned After
197,634
SEC Form 4
Stout Jay S
Sell
Chief Technology Officer
IMVT Jan 7, 2026
Avg Cost/Share
$26.72
Shares
1,203
Total Value
$31,914.08
Owned After
197,634
Van Tuyl Christopher
Sell
Chief Legal Officer
IMVT Dec 18, 2025
Avg Cost/Share
$27.08
Shares
10,813
Total Value
$290,942.54
Owned After
149,930
Fromkin Andrew J.
Sell
Director
IMVT Dec 1, 2025
Avg Cost/Share
$23.55
Shares
22,249
Total Value
$517,189.24
Owned After
88,750
Hughes Douglas J.
Sell
Director
IMVT Dec 1, 2025
Avg Cost/Share
$23.55
Shares
15,000
Total Value
$348,665.38
Owned After
120,773
Gloria Melanie
Sell
Chief Operating Officer
IMVT Nov 20, 2025
Avg Cost/Share
$23.76
Shares
12,626
Total Value
$298,237.29
Owned After
175,886
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Stout Jay S | IMVT | Chief Technology Officer | Jan 21, 2026 | Sell | $26.03 | 1,977 | $51,461.31 | 197,634 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jan 7, 2026 | Sell | $26.72 | 1,203 | $31,914.08 | 197,634 | |
| Van Tuyl Christopher | IMVT | Chief Legal Officer | Dec 18, 2025 | Sell | $27.08 | 10,813 | $290,942.54 | 149,930 | |
| Fromkin Andrew J. | IMVT | Director | Dec 1, 2025 | Sell | $23.55 | 22,249 | $517,189.24 | 88,750 | |
| Hughes Douglas J. | IMVT | Director | Dec 1, 2025 | Sell | $23.55 | 15,000 | $348,665.38 | 120,773 | |
| Gloria Melanie | IMVT | Chief Operating Officer | Nov 20, 2025 | Sell | $23.76 | 12,626 | $298,237.29 | 175,886 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
GuruFocus.com
Husqvarna AB (HSQVY) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
➖
AI Sentiment
Neutral
4/10
GuruFocus.com
Matthews Emerging Markets Small Companies Fund's Strategic Moves: Spotlight on Lundin Mining Corp
➖
AI Sentiment
Neutral
5/10
GuruFocus.com
Stillfront Group AB (STLFF) Full Year 2025 Earnings Call Highlights: Strategic Shifts Amid ...
➖
AI Sentiment
Neutral
4/10
GlobeNewswire
Engineering & Construction Industry Megaprojects and Technological Advancements 2026
📈
AI Sentiment
Highly Positive
9/10
PR Newswire
Global HVAC Air Quality Monitoring Market Projected to Surge to USD 75.4 Billion by 2035 as Intelligent Building Mandates and Health-Conscious Infrastructure Redefine Modern Facilities
📈
AI Sentiment
Highly Positive
8/10
GuruFocus.com
Borregaard ASA (BRRDF) Q4 2025 Earnings Call Highlights: Record EBITDA Amidst Challenges
📊
AI Sentiment
Positive
6/10
GuruFocus.com
Wartsila Corp (WRTBF) Full Year 2025 Earnings Call Highlights: Record Profits and Strategic ...
📊
AI Sentiment
Positive
7/10
Compare IMVT vs Leading Stocks
See how IMVT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.